$MIRM

Mirum Pharmaceuticals, Inc.

Runway:5 mo

NasdaqMarket cap: —CIK 0001759425

Upcoming catalysts

2 surfaced

Volixibat · Intrahepatic Cholestasis of Pregnancy

“The Company has a pre-New Drug Application ("NDA") meeting for volixibat in PSC scheduled with the U.S. Food and Drug Administration ("FDA") in summer 2026, with a planned NDA submission in the second half of 2026.”

Date TBD

NDA/BLA filedDate TBD

$MIRMMirum Pharmaceuticals, Inc.

livmarli

“Sandoz, Inc. ("Sandoz"), providing notification to the Company that Sandoz has submitted an Abbreviated New Drug Application ("ANDA") to the U.S. Food and Drug Administration ("FDA"), seeking approval of a generic version of Livmarli ® (maralixibat)”

Date TBD

Drug pipeline

livmarli

ctexli

Brelovitug (BJT-778)

Chronic Hepatitis D

Livmarli Oral Product

Alagille Syndrome

Maralixibat

Progressive Familial Intrahepatic Cholestasis (PFIC)

Low dose of MRM-3379

Fragile X Syndrome

Cholbam

Bile Acid Synthesis Disorders

Brelovitug 300 mg

Chronic Hepatitis D Infection

Cholic Acids

Infantile Refsum's Disease

LUM001

Alagille Syndrome

Cholic acid

Inborn Errors of Bile Acid Synthesis

Placebo

Healthy Volunteers

SHP626

Non-Alcoholic Steatohepatitis

Volixibat

Intrahepatic Cholestasis of Pregnancy

Blinded CDCA 250 mg TID

CTX

LUM001 (Maralixibat)

Alagille Syndrome

Recent & active trials

NCT	Drug	Phase	Status	Primary completion
NCT03115086	Cholbam	—	Active Not Recruiting	2038-07-01
NCT07290257	Livmarli Oral Product	Phase 4	Recruiting	2030-09-22
NCT06907290	Brelovitug 300 mg	Phase 3	Active Not Recruiting	2029-05-01
NCT06193928	livmarli	—	Recruiting	2028-09-20
NCT07209462	Low dose of MRM-3379	Phase 2	Recruiting	2027-10-01
NCT07454837	Brelovitug (BJT-778)	Phase 3	Recruiting	2027-08-31
NCT07200908	Brelovitug 300 mg	Phase 3	Recruiting	2027-06-30
NCT05050136	Volixibat	Phase 2	Recruiting	2027-04-01
NCT06553768	Maralixibat	Phase 3	Active Not Recruiting	2026-10-01
NCT07298330	Brelovitug 300 mg	Phase 3	Recruiting	2026-08-01
NCT04663308	Volixibat	Phase 2	Active Not Recruiting	2026-06-01
NCT04185363	Maralixibat	Phase 3	Completed	2025-04-23
NCT04729751	Maralixibat	Phase 2	Completed	2024-12-17
NCT04168385	Maralixibat	Phase 2	Completed	2024-09-04
NCT04524390	Maralixibat	Phase 2	Completed	2023-11-07
NCT04270682	Blinded CDCA 250 mg TID	Phase 3	Completed	2023-07-13
NCT04718961	Volixibat	Phase 2	Terminated	2022-12-07
NCT03905330	Maralixibat	Phase 3	Completed	2022-09-01
NCT02047318	LUM001	Phase 2	Completed	2020-06-17
NCT03353454	Maralixibat	Phase 3	Withdrawn	2020-06-15